Table 3 Univariate analysis of treatment in case and control groups
From: Children systemic lupus erythematosus-associated pancreatitis
Variables | SLE with pancreatitis (N = 12) | SLE without pancreatitis (N = 48) | P |
|---|---|---|---|
Steroid, n (%) | 12 (100 %) | 47 (97.9 %) | 0.614 |
Methylprednisolone pulse during remission induction, n (%) | 11 (91.7 %) | 5 (10.4 %) | < 0.001 |
Adequate methylprednisolone/prednisolone during remission induction | 1 (8.3 %) | 42 (87.5 %) | < 0.001 |
Immunosuppressant | |||
Hydroxychloroquine, n (%) | 12 (83.3 %) | 43 (89.6 %) | 0.243 |
Cyclophosphamide during induction, n (%) | 10 (83.3 %) | 16 (33.3 %) | 0.002 |
Mycophenolate mofetil during induction, n (%) | 0 (0 %) | 19 (39.6 %) | 0.008 |
Mycophenolate mofetil during maintenance, n (%) | 7 (83.3 %) | 16 (33.3 %) | 0.111 |
Methotrexate, n (%) | 0 (0 %) | 5 (10.4 %) | 0.243 |
Tacrolimus, n (%) | 0 (0 %) | 4 (8.3 %) | 0.301 |
Cyclosporine, n (%) | 1 (8.3 %) | 2 (4.2 %) | 0.605 |
Leflunomide, n (%) | 0 (0 %) | 2 (4.2 %) | 0.472 |
Belimumab, n (%) | 1 (8.3 %) | 1 (2.1 %,) | 0.281 |
Rituximab, n (%) | 1 (8.3 %) | 6 (12.5 %) | 0.688 |
Plasma exchange, n (%) | 2 (16.7 %) | 0 (0 %) | 0.004 |